Notice: Educational. Affiliate links. Not medical advice.
Data from published clinical trials, complete statistical distribution, and documented cases with honest disclaimers. No manipulated photos, no empty promises.
⚠️ Important before continuing: The results you'll see below come from controlled clinical trials with medical monitoring and behavioral support. Individual results vary significantly. Some patients lose much less than the average, others more. Factors like genetics, diet, exercise, sleep, mental health, and other medications massively influence outcomes. Transformation images without complete statistical context are marketing content, not clinical information — we always look for peer-reviewed data.
Direct data from peer-reviewed publications.
Semaglutide
STEP-1 (NEJM 2021)
N = 1,961 adults with BMI ≥ 30 without diabetes. Dose 2.4 mg weekly + behavioral intervention.
Tirzepatide
SURMOUNT-1 (NEJM 2022)
N = 2,539 adults with obesity. Dose 5, 10, 15 mg weekly + behavioral intervention.
Retatrutide
Phase 2 (NEJM 2023)
N = 338. Preliminary Phase 2 data. Not yet FDA-approved. Complete Phase 3 data pending.
Primary sources: Wilding et al. NEJM 2021, Jastreboff et al. NEJM 2022, Jastreboff et al. NEJM 2023. Individual results vary — see quartile detail.
The strongest predictors according to clinical literature.
Treatment adherence
People who take the medication every week lose 2-3x more than those who skip doses.
Behavioral support
Programs with coaching or monthly follow-up generate ~40% more loss than programs that only ship medication.
Diet quality
Mediterranean or high-protein: better result. Ultra-processed: much worse.
Strength training
2-3 sessions/week protect muscle mass and improve body composition.
7-9 hours of sleep
Insufficient sleep diminishes the effects of any GLP-1.
Genetics
Variants in MC4R, FTO, and other loci predict response. Not yet routinely tested.
Month 1: 2-5% loss + GI adjustment
Initial nausea common, manageable with low starting dose. Visible loss in waist.
Month 3: 8-12% accumulated
Already on maintenance dose. Notable size change. Energy stabilized.
Month 6: 13-18% accumulated
Mid-point. Some brief plateau here — normal. Time to evaluate dose and routine.
Month 12: 18-24% accumulated (tirzepatide)
Decision point: continue to maintenance or evaluate transition.
Ranges based on SURMOUNT-1, with conservative adjustments for general population. Individual results vary significantly.
Evaluate the compliant telehealth programs we recommend.
See recommended programs →